Yu, Alice Lin-Tsing 陳鈴津

Yu ALT_6x7客座講座




  • M.D., National Taiwan University, 1968
  • M.S., Yale University, 1969
  • Ph.D., Microbiology/Immunology, University of Chicago, 1973
  • Assistant Professor through Professor of Pediatrics, University of California, San Diego, 1977-2001
  • Professor and Chief, Pediatric Hematology/Oncology, University of California, San Diego, 2001-2003
  • Distinguished Professor and Deputy Director, Genomics Research Center, Academia Sinica, 2003-2013


  • Biotech All-Stars, San Diego Padre, Qualcome Stadium, 1997
  • Health Hero of year 2000, awarded by the Epilepsy Society Doctor of the year, Honorable Mention, UCSD Medical Center, 2000
  • Honored at the S.D. Padres Stadium for launching a new vaccine study for children with neuroblastoma, 2000
  • Recipient of the Year 2000 “Key to Life” Award from the Leukemia & Lymphoma Society, 2001
  • Honored at the San Diego Padres Stadium as Community Health Heros, 2001
  • The 19th Wang Min-Ning Memorial Award for Outstanding Contribution to the Development Mediccal Sciene and Technology, National Health and Society, 2009
  • The 55th Academic Award from the Ministry of Education, 2011


Antibody mediated killing of cancer cells (Cheson et al, NEJM, 2008)

Dr. Yu has a longstanding interest in translational research, aiming to bridge the gap between laboratory research and clinical medicine. In particular, she has been pursuing therapy targeting specific molecular alterations in cancer from small molecules to biologics. She has led several nationwide cooperative group clinical trials in the USA. As a pioneer in cancer immunotherapy targeting GD2, she has taken an anti-GD2 monoclonal antibody from IND application through phase I, II and III clinical trial which culminated in significant improvement in the outcome of high risk neuroblastoma. She is now developing therapeutic cancer vaccines targeting GD2 with anti-idiotypic antibody for neuroblastoma and melanoma, and glycans such as GloboH and Gb5 with synthetic carbohydrates for the treatment of epithelial cancers including cancers of breast, lung, ovary, pancreas, etc. She has a broad spectrum of research interest ranging from molecular signature of cancer and cancer stem cells, cell cycle regulation, in vitro and in vivo preclinical screening of novel therapeutic agents, design, development and implementation of clinical protocols for immunotherapy and other clinical investigation.

陳鈴津博士長期致力於轉譯醫學研究,期能建立實驗研究與臨床醫學之間的橋樑。探討癌症的相關分子變化,進而發展癌症的新療方。陳博士同時也領導美國數個全國性合作的臨床試驗。她是首位以GD2進行癌症免疫療法的先驅,經過臨床實驗已證實,GD2單株抗體能有效改善高風險性的神經母細胞瘤病情。目前正在研發以GD2為標的的特異性抗體(anti-idiotypic Ab),做為治療神經母細胞瘤、黑色素瘤的癌症疫苗,或以合成的醣類做抗癌疫苗,針對醣質-GloboH、Gb5為抗原,治療上皮細胞癌,例如乳癌、肺癌、卵巢癌或胰腺癌等。陳博士的研究興趣廣泛,含括癌症相關分子標的、癌症幹細胞、細胞週期調控的探討,新藥開發臨床前體外及體內的篩選實驗、免疫療法的臨床實驗設計、執行及其相關臨床研究。